Company Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection.
The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.
The company was incorporated in 2012 and is based in Alpharetta, Georgia.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Gregory Duncan |
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia 30009 United States | |
| Phone | 866 620 8655 |
| Website | dwtx.com |
Stock Details
| Ticker Symbol | DWTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818844 |
| CUSIP Number | 92829J203 |
| ISIN Number | US92829J2033 |
| Employer ID | 85-4314201 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory Duncan | Chairman and Chief Executive Officer |
| Dr. William L. Pridgen M.D. | Founder and Member of Scientific Advisory Board |
| Angela Walsh | Chief Financial Officer, Secretary and Treasurer |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Ralph D. Grosswald M.P.H. | Senior Vice President of Operations |
| Carol Duffy Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 23, 2026 | PRE 14A | Other preliminary proxy statements |
| Jan 20, 2026 | 8-K | Current Report |
| Jan 15, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 13, 2026 | 8-K | Current Report |
| Jan 13, 2026 | 424B5 | Filing |
| Jan 8, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 28, 2025 | 8-K | Current Report |
| Nov 28, 2025 | 424B5 | Filing |
| Nov 25, 2025 | SCHEDULE 13D/A | Filing |
| Nov 21, 2025 | 8-K | Current Report |